Neil G. Almstead,Peter Seongwoo Hwang,Young-Choon Moon
申请号:
US16380218
公开号:
US20190231754A1
申请日:
2019.04.10
申请国别(地区):
US
年份:
2019
代理人:
摘要:
The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.